Company intelligence / Profile preview
KalVista Pharmaceuticals
Cambridge, Massachusetts, United Stateskalvista.com ↗
- Ownership
- Public · KALV
- Employees
- ~130
- Development stage
- NDA
01
Overview
Sebetralstat demonstrated positive results in pivotal Phase III clinical trials for on-demand treatment of hereditary angioedema. It offers an oral alternative to injectable therapies and has received Fast Track and Orphan Drug Designations from the FDA. Regulatory filings are underway globally; if approved it will be the first oral on-demand HAE therapy worldwide.
- Therapeutic areas
- ImmunologyCardiovascular
- Modalities
- Small molecules (oral protease inhibitors, specifically kallikrein inhibitors)
- Industry
- Biotech
02
Drug pipeline
11 assets10 more assets in the full pipeline.
Request access →03
Partnerships
Kaken Pharmaceutical Co., Ltd. – exclusive commercialization partner for sebetralstat in Japan; includes upfront/milestone payments and royalties based on salesDRI Healthcare Trust – synthetic royalty financing agreement related to sebetralstat future revenues
04
Financials
- Market cap
- $1.4B
- Total revenue
- $59.9M
- Enterprise value
- $1.4B
Beyond the preview
Go deeper on KalVista Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KalVista Pharmaceuticals.